share_log

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

Benzinga ·  Sep 22, 2024 14:04

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?

  1. Summit Therapeutics Inc. (NASDAQ:SMMT) stock declined 23.61%. The company announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented at the 2024 ESMO Annual Meeting.
  2. Joint Stock Company Kaspi.kz (NASDAQ:KSPI) stock tumbled 21.66% after Culper Research issued a short report on the company.
  3. BioMarin Pharmaceutical Inc (NASDAQ:BMRN) stock lost 16.74% last week following strong dwarfism drug data from rival Ascendis Pharma (NASDAQ:ASND).
  4. Rivian Automotive, Inc. (NASDAQ:RIVN) lost 13.26% last week.
  5. FedEx Corporation (NYSE:FDX) stock fell 11.08% after the company reported worse-than-expected Q1 financial results and cut FY25 guidance.
  6. BioNTech SE (NASDAQ:BNTX) stock decreased 9.01%. Pfizer, Inc. (NYSE:PFE) and BioNTech received positive CHMP opinion for omicron KP.2-adapted COVID-19 vaccine in the European Union.
  7. Arthur J. Gallagher & Co. (NYSE:AJG) stock fell 7.17%. Several analysts raised the price target on the stock.
  8. Chewy, Inc. (NYSE:CHWY) shares declined 6.97% after the company announced a selling stockholder's public offering of shares and a concurrent share repurchase.
  9. Novo Nordisk A/S (NYSE:NVO) stock fell 6.93% after headline results from the mid-stage study of monlunabant in obese patients.
  10. Murphy USA Inc. (NYSE:MUSA) shares fell 6.90% after JP Morgan downgraded the stock from Neutral to Underweight but raised its price target from $415 to $435.

Also Read:

  • Constellation Energy, Li Auto And Carvana Are Among Top 11 Large Cap Gainers Last Week (Sept 16-Sept 20): Are The Others In Your Portfolio?

Photo via Shutterstock

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment